Latest news with #DXCM
Yahoo
07-07-2025
- Business
- Yahoo
What You Need to Know Ahead of DexCom's Earnings Release
DexCom, Inc. (DXCM), a San Diego-based medical device company with a $32.5 billion market cap, specializes in continuous glucose monitoring (CGM) systems. Its technology includes a small, implantable sensor that tracks glucose levels beneath the skin and transmits data to an external receiver in real-time. DexCom is slated to report its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30. Ahead of the event, analysts expect DXCM to report a profit of $0.45 per share on a diluted basis, up 4.7% from $0.43 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions. Chevron Stock's 4.6% Dividend Yield and 1.67% One Month Short Put Yield Make CVX a Buy Tariff Dealine, Fed Minutes and Other Key Thing to Watch this Week SoFi Stock Is Betting on Crypto Again. How Should You Play SOFI Stock Here? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect DXCM to report EPS of $2.03, up 23.8% from $1.64 in fiscal 2024. Its EPS is expected to rise 24.6% year over year to $2.53 in fiscal 2026. Over the past 52 weeks, DXCM's shares have dipped 25.2%, underperforming the S&P 500's ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund's (XLV) 5.4% dip over the same time frame. On July 1, DexCom shares fell over 4% after the U.S. government proposed changes to payment schedules and introduced a competitive bidding program for diabetes devices, impacting the broader glucose monitoring and insulin pump sector. Nevertheless, analysts' consensus opinion on DXCM stock is very positive, with an overall 'Strong Buy' rating. Out of 25 analysts covering the stock, 20 advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' and four give a 'Hold.' DXCM's average analyst price target is $99.68, indicating a potential upside of 20.2% from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. DexCom is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 0.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that DXCM has returned about 7.5% since the start of the calendar year. In comparison, Medical companies have returned an average of -2.9%. This shows that DexCom is outperforming its peers so far this year. One other Medical stock that has outperformed the sector so far this year is Bayer Aktiengesellschaft (BAYRY). The stock is up 59.4% year-to-date. The consensus estimate for Bayer Aktiengesellschaft's current year EPS has increased 6.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 84 individual stocks and currently sits at #186 in the Zacks Industry Rank. This group has lost an average of 7.5% so far this year, so DXCM is performing better in this area. Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 10-stock industry is ranked #53. The industry has moved -0.3% so far this year. Investors with an interest in Medical stocks should continue to track DexCom and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research 登入存取你的投資組合
Yahoo
03-07-2025
- Business
- Yahoo
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. DexCom is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 0.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that DXCM has returned about 7.5% since the start of the calendar year. In comparison, Medical companies have returned an average of -2.9%. This shows that DexCom is outperforming its peers so far this year. One other Medical stock that has outperformed the sector so far this year is Bayer Aktiengesellschaft (BAYRY). The stock is up 59.4% year-to-date. The consensus estimate for Bayer Aktiengesellschaft's current year EPS has increased 6.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 84 individual stocks and currently sits at #186 in the Zacks Industry Rank. This group has lost an average of 7.5% so far this year, so DXCM is performing better in this area. Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 10-stock industry is ranked #53. The industry has moved -0.3% so far this year. Investors with an interest in Medical stocks should continue to track DexCom and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data
CNBC
03-07-2025
- Business
- CNBC
Top stock picks for the second half of the year from BTIG
As the second half of the year kicks off, BTIG's list of recommended stock picks could win big. The first half of 2025 was marred by raging volatility resulting from President Donald Trump's universal tariff policies and armed conflict in the Middle East. But stocks have more than made up for heightened uncertainty, with the S & P 500 bouncing back more than 20% from the April low to reach three all-time highs in the past four sessions. Goldman Sachs noted that this marked the index's fastest recovery ever from a decline of more than 15%. Now Goldman is optimistic that the latest move has legs, at least for the next few weeks. And several other banks, including Citigroup , JPMorgan , Barclays , Deutsche Bank and RBC , have all raised their year-end targets for the market. In a Tuesday note, BTIG analysts shared their highest conviction investment ideas for the next 12 months, including the following stocks: Starbucks , up 4% this year, was recommended by BTIG. The brokerage firm's price target of $105 per share is approximately 11% above where the coffee chain closed Wednesday. "While progress has taken longer to materialize, frustrating some investors with shares only slightly positive in the first half, we still believe it is happening and will set the stage for outsized same-store sales and earnings growth in 2026 and beyond," wrote BTIG analyst Peter Saleh. "The recovery trajectory now looks like it will emerge towards year-end 2025 and into the first half of next year. Granted this is further back than we expected six months ago, but we still expect it will catalyze shares once it does emerge." BTIG believes that shares of Dexcom could rise 30% from here, based on Wednesday's close. The maker of continuous glucose monitoring (CGM) systems has already risen 7.5% year to date, although the stock tumbled Tuesday after the Centers for Medicare and Medicaid Services proposed competitive bidding for CGM and infusion pump manufacturers. BTIG wrote on Tuesday that Dexcom remains its top large-cap stock pick for the second half of the year. "The company is continuing its turnaround, with positive trends from late last year persisting in Q1," wrote analyst Marie Thibault. "We believe DXCM is on the right track to meet expectations, return to high-teens or better sales growth in 2H25 and beyond, and meet its [lomg-range planning] targets. We think shares can continue to steadily re -rate throughout the rest of 2025 as DXCM gets back to its winning ways." Other stocks that BTIG rates highly include AppLovin , Capital One Financial and Snowflake .
Business Wire
10-06-2025
- Business
- Business Wire
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purported market share. However, beginning on April 25, 2024, DexCom made its first in a series of public corrective disclosures announcing that the company's growth and business prospects were far lower than it had previously claimed. By the time the company made its final corrective disclosure on July 25, 2024, the price of DexCom's shares had plummeted by over 40.6%. Current stockholders who held their DexCom stock before April 28, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights in this matter. You can click or copy and paste the following link to join this investigation: About Johnson Fistel, PLLP: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
